Algernon Pharmaceuticals ($AGN.c $AGNPF) recently came onto my radar following the Market Herald's Power Play interview with Chris Moreau and I'm quite intrigued by its business model and potential as a clinical-stage drug development company so here's some of my notes on them:
AGN has a unique approach to drug discovery based on drug repurposing by finding drugs that have been approved through clinical trials outside of the US and Europe. This allows AGN to skip quite a few steps while de-risking and saving millions of dollars and multiple years on the drug development timeline.
AGN has met the co-primary endpoint in its Phase 2 proof of concept study evaluating NP-120 which is being evaluated for the potential treatment of IPF and chronic cough.
The data was quite compelling as it showed the efficacy in both IPF and chronic cough patients, either maintaining or improved lung function over a 12-week treatment period!
AGN plans to file a pre-IND application with the US FDA for a Phase 2b IPF study; AGN has already filed a pre-IND application for chronic cough.
Going to be doing some more DD & keeping an eye on AGN for now, but I'm definitely interested as bringing a new IPF treatment that also reduced chronic cough to the market would be quite significant.
https://themarketherald.ca/algernon-pharmaceuticals-hits-co-primary-endpoint-in-its-phase-2-study-of-ifenprodil-for-idiopathic-pulmonary-fibrosis-and-chronic-cough-2022-07-18/